Renal Insufficiency - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 54 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Renal Insufficiency - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Renal Insufficiency - Pipeline Review, H2 2014', provides an overview of the Renal Insufficiency's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Renal Insufficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Insufficiency and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Renal Insufficiency
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Renal Insufficiency and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Renal Insufficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Renal Insufficiency pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Renal Insufficiency
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Renal Insufficiency pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Renal Insufficiency Overview 6
Therapeutics Development 7
Pipeline Products for Renal Insufficiency - Overview 7
Pipeline Products for Renal Insufficiency - Comparative Analysis 8
Renal Insufficiency - Therapeutics under Development by Companies 9
Renal Insufficiency - Pipeline Products Glance 10
Clinical Stage Products 10
Renal Insufficiency - Products under Development by Companies 11
Renal Insufficiency - Companies Involved in Therapeutics Development 12
Boehringer Ingelheim GmbH 12
Elcelyx Therapeutics, Inc. 13
Nippon Zoki Pharmaceutical Co., Ltd. 14
Novartis AG 15
Shire Plc 16
The Medicines Company 17
Renal Insufficiency - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
(meropenem+ RPX-7009) - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
afatinib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BHQ-880 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
LHW-090 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
metformin hydrochloride DR - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
metformin hydrochloride enteric-coated - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
NZ-419 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
SHP-627 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Renal Insufficiency - Recent Pipeline Updates 42
Renal Insufficiency - Dormant Projects 51
Renal Insufficiency - Discontinued Products 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables
Number of Products under Development for Renal Insufficiency, H2 2014 7
Number of Products under Development for Renal Insufficiency - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Products under Development by Companies, H2 2014 11
Renal Insufficiency - Pipeline by Boehringer Ingelheim GmbH, H2 2014 12
Renal Insufficiency - Pipeline by Elcelyx Therapeutics, Inc., H2 2014 13
Renal Insufficiency - Pipeline by Nippon Zoki Pharmaceutical Co., Ltd., H2 2014 14
Renal Insufficiency - Pipeline by Novartis AG, H2 2014 15
Renal Insufficiency - Pipeline by Shire Plc, H2 2014 16
Renal Insufficiency - Pipeline by The Medicines Company, H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Assessment by Combination Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Renal Insufficiency Therapeutics - Recent Pipeline Updates, H2 2014 42
Renal Insufficiency - Dormant Projects, H2 2014 51
Renal Insufficiency - Discontinued Products, H2 2014 52